The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL
Minor histocompatibility antigens (mHAg's) are peptides encoded by polymorphic genes that are presented by major histocompatibility complex (MHC) molecules and recognized by T cells in recipients of allogeneic hematopoietic cell transplants. Here we report that an alternative transcript of the...
Saved in:
Published in | Blood Vol. 107; no. 9; pp. 3779 - 3786 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Washington, DC
Elsevier Inc
01.05.2006
The Americain Society of Hematology 2006 by The American Society of Hematology |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Minor histocompatibility antigens (mHAg's) are peptides encoded by polymorphic genes that are presented by major histocompatibility complex (MHC) molecules and recognized by T cells in recipients of allogeneic hematopoietic cell transplants. Here we report that an alternative transcript of the proliferation-associated nuclear element 1 (PANE1) gene encodes a novel human leukocyte antigen (HLA)-A*0301-restricted mHAg that is selectively expressed in B-lymphoid cells. The antigenic peptide is entirely encoded within a unique exon not present in other PANE1 transcripts. Sequencing of PANE1 alleles in mHAg-positive and mHAg-negative cells demonstrates that differential T-cell recognition is due to a single nucleotide polymorphism within the variant exon that replaces an arginine codon with a translation termination codon. The PANE1 transcript that encodes the mHAg is expressed at high levels in resting CD19+ B cells and B-lineage chronic lymphocytic leukemia (B-CLL) cells, and at significantly lower levels in activated B cells. Activation of B-CLL cells through CD40 ligand (CD40L) stimulation decreases expression of the mHAg-encoding PANE1 transcript and reciprocally increases expression of PANE1 transcripts lacking the mHAg-encoding exon. These studies suggest distinct roles for different PANE1 isoforms in resting compared with activated CD19+ cells, and identify PANE1 as a potential therapeutic target in B-CLL. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reprints: Edus H. Warren, Program in Immunology, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D3-100, PO Box 19024, Seattle, WA 98109-1024; e-mail: ehwarren@u.washington.edu. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734. Supported by grants from the Elsa U. Pardee Foundation, the Lauri Strauss Leukemia Foundation, the Marrow Foundation/National Marrow Donor Program Amy Strelzer Manasevit Scholars Program for the Study of Posttransplant Complications, and a Junior Faculty Clinical Scholar Award from the American Society of Hematology (A.G.B.), a Lilly Clinical Investigator Award from Damon Runyon Cancer Research Foundation (E.H.W.), a grant from the Leukemia & Lymphoma Society (S.R.R., SCOR 7040), and National Institutes of Health (NIH) grants AI44134 and AI20963 (V.H.E.), AI33993 (D.F.H.), CA18029 (S.R.R.), and CA106512 (E.H.W.). Prepublished online as Blood First Edition Paper, January 3, 2006; DOI 10.1182/blood-2005-08-3501. |
ISSN: | 0006-4971 1528-0020 |
DOI: | 10.1182/blood-2005-08-3501 |